MedTrace Logo

Effects of ECA on Quality of Life in Head and Neck Cancer Patients Suffering From Cetuximab-induced Rhagades

NCT01693159 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2017-09-25

No results posted yet for this study

Summary

The SUPPORT trial is an open-label, prospective, randomized, national multicenter intervention study to evaluate the effectiveness of ethyl-2-cyanoacrylate versus the standard treatment of each institution on the pain intensity and QoL in patients with locally advanced head and neck cancer suffering from painful cetuximab-induced rhagades during radioimmunotherapy.

Conditions

Interventions

DEVICE

ECA

In the experimental arm patients will be topically treated with the liquid glue ethyl-2-cyanoacrylate (ECA).

OTHER

Standard topical treatment of the institution, e.g. Lotio

Standard treatment of the institution to treat painful cetuximab-induced rhagades

Sponsors & Collaborators

  • Heidelberg University

    collaborator OTHER

  • iOMEDICO AG

    collaborator INDUSTRY

  • National Center for Tumor Diseases, Heidelberg

    lead OTHER

Principal Investigators

  • Karin Potthoff, MD · National Center for Tumor Diseases, Heidelberg

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2018-07-31
Completion
2018-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01693159 on ClinicalTrials.gov